biopsy-needle
(2)
Ted Belleza
Ted Belleza is the founder, President and CEO of URO-1, Inc., a medical device company based in Greensboro, North Carolina that develops the SUREcore biopsy needle and coreCARE specimen-retrieval kit for prostate and soft tissue biopsy. A serial MedTech entrepreneur with more than 35 years of business experience and prior roles at Gynesonics (acquired by Hologic), Endosee (acquired by CooperSurgical) and LiveLeaf Bioscience, Belleza came out of retirement after his own prostate cancer experience to redesign what he calls an antiquated biopsy procedure, aiming to give physicians bigger, better and more consistent tissue samples.
URO-1, Inc.
URO-1, Inc. is a Greensboro, North Carolina medical device company modernizing the prostate biopsy, a procedure its founder describes as largely unchanged in decades. Founded in 2017 by prostate cancer survivor and serial MedTech entrepreneur Ted Belleza, URO-1 makes the FDA-cleared SUREcore biopsy needle and coreCARE tissue transfer system, a paired platform built to collect larger, more intact tissue cores and preserve their integrity on the way to pathology. The company reports its needle hit 92% targeting accuracy in MRI-ultrasound fusion biopsies versus 36% for conventional needles, and began commercial launch in January 2025 following an $8 million Series A.